BAY 12-8039 (moxifloxacin) Phase III study of the treatment of skin and skin structure infections

Jiro Arata, Shinichi Watanabe, Yoshiki Miyachi, Masutaka Furue

Research output: Contribution to journalArticle

Abstract

The clinical efficacy and safety of BAY 12-8039 (moxifloxacin: MFLX), a novel new quinolone compound, were evaluated in patients with skin and structure infections. The dosage of MFLX was 400 mg once daily for 7 days. The overall clinical efficacy was 78.6% (22/28) in group I-a, 93.8% (15/16) in group I-b, 73.2% (41/56) in group II-a, 100% (12/12) in group II-b and 45.5% (15/33) in group III. The bacteriological eradication rate was 78.3% (18/23) in group I-a, 75.0% (12/16) in group I-b, 75.5% (37/ 49) in group II-a, 100% (4/4) in group II-b and 69.0% (20/29) in group III. The patients for group III did not improve sufficiently even though causative organisms were eliminated. It may be because infections in group III were based on local underlying conditions. Therefore, antibacterial drugs alone are insufficient to improve these infections. For group III, further assessment is required. The incidence of adverse drug reactions was 25.6% (40/156). The most common adverse drug reactions were digestive disorders, such as nausea, diarrhea, and stomach discomfort. All of symptoms were mild to moderate. The results suggest that MFLX tablet will be clinically useful for the treatment of skin and skin structure infections.

Original languageEnglish
Pages (from-to)60-73
Number of pages14
JournalJapanese Journal of Chemotherapy
Volume53
Issue numberSUPPL. 3
Publication statusPublished - Dec 1 2005

Fingerprint

Skin
Infection
Drug-Related Side Effects and Adverse Reactions
Quinolones
Therapeutics
Nausea
Tablets
Diarrhea
Stomach
Safety
moxifloxacin
Incidence
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

BAY 12-8039 (moxifloxacin) Phase III study of the treatment of skin and skin structure infections. / Arata, Jiro; Watanabe, Shinichi; Miyachi, Yoshiki; Furue, Masutaka.

In: Japanese Journal of Chemotherapy, Vol. 53, No. SUPPL. 3, 01.12.2005, p. 60-73.

Research output: Contribution to journalArticle

Arata, Jiro ; Watanabe, Shinichi ; Miyachi, Yoshiki ; Furue, Masutaka. / BAY 12-8039 (moxifloxacin) Phase III study of the treatment of skin and skin structure infections. In: Japanese Journal of Chemotherapy. 2005 ; Vol. 53, No. SUPPL. 3. pp. 60-73.
@article{6f0ab6806a4f469ca54c0e1c9c775097,
title = "BAY 12-8039 (moxifloxacin) Phase III study of the treatment of skin and skin structure infections",
abstract = "The clinical efficacy and safety of BAY 12-8039 (moxifloxacin: MFLX), a novel new quinolone compound, were evaluated in patients with skin and structure infections. The dosage of MFLX was 400 mg once daily for 7 days. The overall clinical efficacy was 78.6{\%} (22/28) in group I-a, 93.8{\%} (15/16) in group I-b, 73.2{\%} (41/56) in group II-a, 100{\%} (12/12) in group II-b and 45.5{\%} (15/33) in group III. The bacteriological eradication rate was 78.3{\%} (18/23) in group I-a, 75.0{\%} (12/16) in group I-b, 75.5{\%} (37/ 49) in group II-a, 100{\%} (4/4) in group II-b and 69.0{\%} (20/29) in group III. The patients for group III did not improve sufficiently even though causative organisms were eliminated. It may be because infections in group III were based on local underlying conditions. Therefore, antibacterial drugs alone are insufficient to improve these infections. For group III, further assessment is required. The incidence of adverse drug reactions was 25.6{\%} (40/156). The most common adverse drug reactions were digestive disorders, such as nausea, diarrhea, and stomach discomfort. All of symptoms were mild to moderate. The results suggest that MFLX tablet will be clinically useful for the treatment of skin and skin structure infections.",
author = "Jiro Arata and Shinichi Watanabe and Yoshiki Miyachi and Masutaka Furue",
year = "2005",
month = "12",
day = "1",
language = "English",
volume = "53",
pages = "60--73",
journal = "Japanese Journal of Chemotherapy",
issn = "1340-7007",
publisher = "Japan Society of Chemotherapy",
number = "SUPPL. 3",

}

TY - JOUR

T1 - BAY 12-8039 (moxifloxacin) Phase III study of the treatment of skin and skin structure infections

AU - Arata, Jiro

AU - Watanabe, Shinichi

AU - Miyachi, Yoshiki

AU - Furue, Masutaka

PY - 2005/12/1

Y1 - 2005/12/1

N2 - The clinical efficacy and safety of BAY 12-8039 (moxifloxacin: MFLX), a novel new quinolone compound, were evaluated in patients with skin and structure infections. The dosage of MFLX was 400 mg once daily for 7 days. The overall clinical efficacy was 78.6% (22/28) in group I-a, 93.8% (15/16) in group I-b, 73.2% (41/56) in group II-a, 100% (12/12) in group II-b and 45.5% (15/33) in group III. The bacteriological eradication rate was 78.3% (18/23) in group I-a, 75.0% (12/16) in group I-b, 75.5% (37/ 49) in group II-a, 100% (4/4) in group II-b and 69.0% (20/29) in group III. The patients for group III did not improve sufficiently even though causative organisms were eliminated. It may be because infections in group III were based on local underlying conditions. Therefore, antibacterial drugs alone are insufficient to improve these infections. For group III, further assessment is required. The incidence of adverse drug reactions was 25.6% (40/156). The most common adverse drug reactions were digestive disorders, such as nausea, diarrhea, and stomach discomfort. All of symptoms were mild to moderate. The results suggest that MFLX tablet will be clinically useful for the treatment of skin and skin structure infections.

AB - The clinical efficacy and safety of BAY 12-8039 (moxifloxacin: MFLX), a novel new quinolone compound, were evaluated in patients with skin and structure infections. The dosage of MFLX was 400 mg once daily for 7 days. The overall clinical efficacy was 78.6% (22/28) in group I-a, 93.8% (15/16) in group I-b, 73.2% (41/56) in group II-a, 100% (12/12) in group II-b and 45.5% (15/33) in group III. The bacteriological eradication rate was 78.3% (18/23) in group I-a, 75.0% (12/16) in group I-b, 75.5% (37/ 49) in group II-a, 100% (4/4) in group II-b and 69.0% (20/29) in group III. The patients for group III did not improve sufficiently even though causative organisms were eliminated. It may be because infections in group III were based on local underlying conditions. Therefore, antibacterial drugs alone are insufficient to improve these infections. For group III, further assessment is required. The incidence of adverse drug reactions was 25.6% (40/156). The most common adverse drug reactions were digestive disorders, such as nausea, diarrhea, and stomach discomfort. All of symptoms were mild to moderate. The results suggest that MFLX tablet will be clinically useful for the treatment of skin and skin structure infections.

UR - http://www.scopus.com/inward/record.url?scp=30344438511&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30344438511&partnerID=8YFLogxK

M3 - Article

VL - 53

SP - 60

EP - 73

JO - Japanese Journal of Chemotherapy

JF - Japanese Journal of Chemotherapy

SN - 1340-7007

IS - SUPPL. 3

ER -